Melanotan I (MT-I): 10mg

Regulatory Notice (August 2026): Melanotan II was removed from the FDA Category 2 "Do Not Compound" list on April 15, 2026, following withdrawal of the original nomination. Removal from Category 2 does not authorize compounding — formal FDA rulemaking is still required. Update (August 2026): The FDA has confirmed a second PCAC hearing will convene on or before February 28, 2027 to evaluate Melanotan II, LL-37, injectable GHK-Cu, Dihexa, and PEG-MGF for the 503A Bulk Drug Substances List. Melanotan II remains off the 503A Bulks List pending that review. TGA Notice (June 2026): Australia's Therapeutic Goods Administration formally designated unapproved peptide products — including Melanotan II — as a 2026 compliance enforcement priority. These compounds are not registered therapeutic goods in Australia; they may not be lawfully imported, supplied, or advertised for human therapeutic use. Sources: FDA.gov; tga.gov.au (June 10, 2026); peptideknow.com (PCAC second tranche, July 2026). TGA Active Enforcement (August 4, 2026): TGA officers and NSW Police executed search warrants at two residential properties in New South Wales on August 4, 2026, seizing more than $120,000 worth of illicit peptide and anabolic steroid products. The properties were linked to a social media influencer who had previously been warned by the TGA for importing, relabelling, advertising, and supplying unapproved peptide products — a pattern of supply-side enforcement now escalating beyond warnings to physical raids. Source: TGA media release, tga.gov.au (August 17, 2026). TGA Dosing Safety Alert (August 17, 2026): The TGA published a formal safety alert — "Melanotan II tanning peptide products found to be inconsistently dosed" — after laboratory testing of seized products revealed extreme dosing variance. Testing of five bottles of a nasal spray labelled "Pure Tans Triple Strength 30 MG" showed the estimated amount of Melanotan II varied from 22mg to 54mg per bottle — representing a more than 2× range within products carrying the same label. The TGA also announced it had issued 27 infringement notices totalling AUD$101,412 to a NSW-based individual for the alleged unlawful supply of Melanotan II to Australian consumers. Infringement notices were paid in May 2026. The alert underscores that unregulated Melanotan II products are prescription-only medicines in Australia, carry serious health risks, and may not contain the amount stated on the label. Source: TGA safety alert (tga.gov.au, August 17, 2026); 7News (August 17, 2026); TGA media release on individual issued 27 infringement notices (tga.gov.au). Europol Operation SHIELD VI (February 2026): Between April and November 2025, Europol coordinated Operation SHIELD VI — an international pharmaceutical crime enforcement operation across 30 countries resulting in 3,354 individuals prosecuted and €33 million (approx. $38.6M) in counterfeit medicines and illegal supplements seized, including peptides, doping agents, and anabolic compounds. Results announced February 25, 2026. This operation reinforces that cross-border sale of unregulated injectable compounds, including research peptides, is subject to active multi-jurisdictional enforcement. Sources: Europol press release (europol.europa.eu, February 25, 2026); OLAF; InsideTheGames (February 2026). INTERPOL Operation Pangea XVIII (March–May 2026): Between March 10 and 23, 2026, INTERPOL coordinated Operation Pangea XVIII across 90 countries and territories, targeting illicit pharmaceutical supply chains including online sellers of falsified medicines and unapproved injectables. In the UK alone, over two million doses of illicit medicines valued at £4.6 million were seized at the border. The Danish Medicines Agency reported six websites to police and detained 19 consignments. This operation specifically targeted online and social-media-driven sales of unapproved injectable products. Source: UK Government/MHRA (gov.uk, May 2026); Danish Medicines Agency (laegemiddelstyrelsen.dk, 2026); INTERPOL. Swissmedic / Basel-Landschaft Pratteln Seizure (October 7, 2026): On October 7, 2026, the Basel-Landschaft public prosecutor's office announced a criminal investigation after a September 2026 house search in Pratteln, Switzerland, seized more than 3,200 injection vials of illegally imported peptides plus syringes, packaging materials, and labels — described as the largest seizure of illegally imported peptides in Switzerland to date. Two individuals are under investigation for alleged violations of the Sport Promotion Act and the Therapeutic Products Act; the presumption of innocence applies. The case is linked to the June 22, 2026 cross-agency “Peptides 2026” campaign by Swissmedic, the Federal Office for Customs and Border Security (BAZG/FOCBS), and Swiss Sport Integrity (SSI), which inspected 46 packages of dubious peptide preparations (23 retained). Swiss authorities state that import of and trade in such unapproved injectable peptides is prohibited. Specific active ingredients in the Pratteln vials were not publicly named. This is Swiss domestic enforcement and does not change U.S. 503A/503B compounding status or FDA approval status of research peptides. Sources: Basel-Landschaft Staatsanwaltschaft media release (baselland.ch, 7 October 2026); Swiss federal press release on Peptides 2026 campaign (admin.ch, 30 June 2026); Swissinfo/Keystone-SDA (7 October 2026). NSW Health ED Surge Warning — Australia (October 15–19, 2026): NSW Health issued Safety Information SI:009/26 (15 October 2026) and a public warning after emergency department presentations linked to unapproved peptide products rose from 5 in July 2025 to 217 in September 2026 — 1,180 presentations over 15 months (July 2025–September 2026), with ~18% resulting in hospital admission. About 71% of presentations mentioned retatrutide; others named BPC-157, TB-500, CJC-1295, ipamorelin, Melanotan II, or generic "peptide," including some compounded semaglutide/tirzepatide. A quarter of presentations were ages 16–24; most common diagnoses were GI illness (intractable vomiting, abdominal pain), cardiovascular symptoms, anaphylaxis, injection-site infection, and unexplained acute liver injury or pancreatitis. NSW Chief Health Officer Dr Kerry Chant and Health Minister Ryan Park warned that professional-looking labels, websites, purity claims, reviews, or influencer endorsements are not proof of safety or identity; products are not TGA-assessed. Clinicians are advised to consider unapproved peptide use in differential diagnosis. This is an Australian state public-health and TGA-aligned enforcement signal and does not change U.S. FDA approval or 503A/503B compounding status. Sources: NSW Health SI:009/26 PDF (health.nsw.gov.au, 15 Oct 2026); NSW Health peptides patient page (health.nsw.gov.au); ABC News (19 Oct 2026); SMH (19 Oct 2026); The Daily Aus (19 Oct 2026).